The passage of drugs from the maternal to fetal blood involves crossing several layers of tissue, including the syncytiotrophoblast, fetal connective tissue, and the endothelium of fetal capillaries. The rate-limiting step in this process is the syncytiotrophoblast layer, which covers the placental villi. The mechanisms by which drugs cross the placenta can be categorized into four main types: simple diffusion, facilitated diffusion, active transport, and pinocytosis.
Simple Diffusion
Most drugs, including midazolam and acetaminophen (paracetamol), cross the placenta via simple diffusion. This process relies on the concentration gradient between the maternal and fetal circulations, with drugs moving from areas of higher concentration (typically maternal blood) to areas of lower concentration (fetal blood). Simple diffusion occurs either through the syncytiotrophoblast layer or via water channels (paracellularly). This mechanism does not require energy input and follows Fick’s law of diffusion, which states that the rate of drug diffusion depends on the surface area of the placenta, the concentration gradient across it, and the thickness of the placental membrane.
Written out, the rate of transfer Q/t = K × A × (Cm - Cf) / D, where K is the diffusion constant of the drug (set by its molecular weight, lipid solubility, and degree of ionization), A is the surface area available for exchange, Cm - Cf is the concentration gradient of free drug between maternal and fetal blood, and D is the thickness of the barrier. The drug factors below determine K; the placental factors (surface area, thickness, and blood flow) are taken up in the Factors Affecting Drug Transfer lesson.
Key factors affecting drug diffusion include:
Molecular Weight: Drugs with a molecular weight of less than 500 to 600 Da cross the placenta readily, those between 600 and 1,000 Da cross incompletely, and those above 1,000 Da (heparin, insulin, immunoglobulins) cross very poorly except by a carrier or vesicle. Most anesthetic drugs weigh 200 to 500 Da and thus transfer efficiently.
Lipid Solubility: Lipophilic drugs diffuse more easily across the lipid-rich placental membranes.
Degree of Ionization: Non-ionized forms of drugs cross the placental barrier more readily than ionized forms, because the non-ionized molecule is the lipid-soluble one. The degree of ionization depends on the drug’s pKa and the pH of the blood it sits in, by the Henderson-Hasselbalch relationship. Most anesthetic drugs are weak bases (local anesthetics have a pKa of 7.7 to 8.1 except chloroprocaine at 8.7; most opioids 8 to 9), so at a maternal pH of 7.4 only a fraction is non-ionized and free to cross: lidocaine (pKa 7.9) is about 24% non-ionized at pH 7.4, bupivacaine (pKa 8.1) about 17%, and chloroprocaine (pKa 8.7) about 5%.
This is the basis of ion trapping. Normal fetal pH (about 7.3) is a tenth of a unit below maternal, so a weak base that crosses in its non-ionized form meets a more acidic environment, gains a proton, becomes ionized, and can no longer diffuse back. The equilibrium therefore favors the fetal side even at baseline, and in a distressed, acidotic fetus (pH 7.0 to 7.2) the trapped, ionized fraction grows: Biehl and colleagues showed that fetal lidocaine levels rise as fetal pH falls, and Johnson and colleagues reproduced the same pH dependence for lidocaine and bupivacaine in the perfused human placenta. Fetal acidosis thus raises the fetal load of local anesthetic (and of weak-base opioids) exactly when the fetus tolerates it least, so correcting maternal hypotension and the cause of fetal acidosis protects the fetus more than the choice of local anesthetic does. Maternal alkalosis from hyperventilation works on the other side of the barrier: it increases the non-ionized maternal fraction available to cross while also constricting the uterine vessels.
Protein Binding: Drugs that are highly protein-bound do not readily cross the placenta, as only the free, unbound fraction is available for diffusion. Bupivacaine is about 95% bound to alpha-1 acid glycoprotein and lidocaine about 70%, which is a large part of why bupivacaine's UV/MV ratio at delivery is about 0.3 while lidocaine's is 0.5 to 0.7. Protein binding slows transfer rather than preventing it: bound drug dissociates as free drug crosses, so during a long epidural infusion fetal levels still climb. Fetal plasma also carries less alpha-1 acid glycoprotein and albumin than maternal plasma, so the fetal free fraction is higher and total-concentration ratios understate the active drug the fetus actually sees.
As pregnancy progresses, the placental surface area increases, while the placental membranes become thinner. This enhances the rate of passive diffusion of drugs to the fetus. However, pathological conditions such as infection or inflammation can thicken the placental membranes, reducing the efficiency of this process.
Facilitated Diffusion
Some drugs, such as cephalosporins and glucocorticoids, utilize facilitated diffusion to cross the placenta. This process requires a carrier molecule within the placenta to facilitate drug transport, but like simple diffusion, it does not require energy. Facilitated diffusion is especially important for drugs that are structurally similar to endogenous substances, such as glucose or amino acids, which use specific transporter proteins.
However, facilitated diffusion is subject to saturation, meaning that when the carrier proteins are fully occupied by both the drug and endogenous substrates, the transfer rate of the drug may be reduced. This competition for carrier proteins can limit the transport of both drugs and naturally occurring compounds, affecting the availability of nutrients and medications to the fetus.
Active Transport
Active transport involves the use of energy, typically in the form of ATP, to move drugs against their concentration or electrochemical gradients. This process is mediated by specific carrier proteins and is essential for the transfer of certain drugs that require transport from the mother to the fetus. Examples of drugs that utilize active transport include norepinephrine and dopamine.
The placenta contains two families of active transporters that work in opposite directions. Efflux pumps of the ATP-binding cassette family, P-glycoprotein (ABCB1), breast cancer resistance protein (BCRP, ABCG2), and the multidrug resistance proteins (MRPs), sit mainly on the maternal-facing (microvillous) membrane of the syncytiotrophoblast and pump their substrates back into maternal blood; digoxin, dexamethasone, many chemotherapeutic agents, and opioids such as morphine, methadone, and fentanyl are P-glycoprotein substrates, so the fetus is exposed to less of them than passive diffusion would predict. Uptake carriers of the solute carrier family (for example the serotonin, norepinephrine, and organic cation transporters) move endogenous substances and drugs that resemble them, such as norepinephrine and dopamine, into and across the syncytiotrophoblast. Together these transporters mean the placenta is not a passive filter: it actively limits fetal exposure to some drugs, and inhibitors or genetic variants of P-glycoprotein can raise fetal drug levels.
Pinocytosis
In pinocytosis, the drug becomes engulfed by the placental membrane, forming a vesicle that transports the drug across the syncytiotrophoblast layer. Once inside the vesicle, the drug is released into the fetal circulation. It is a slow, minor route for drugs, but it is the route for large molecules such as immunoglobulin G (IgG), which binds the neonatal Fc receptor (FcRn) inside the vesicle and is carried across to the fetal side intact, providing passive immunity to the fetus.
Pinocytosis is a less common mechanism of drug transfer but is essential for the transport of certain macromolecules that cannot cross the placenta through simple or facilitated diffusion. The process involves the complete encapsulation of the drug in an invagination of the cell membrane, followed by vesicular transport to the fetal side.
